ACHIEVE LIFE SCIENCES, INC. 4

Director Aaron Royston received option and RSU equity awards in Achieve Life Sciences, Inc. totaling 41,700 shares of common stock equivalent as director compensation.

On July 27, 2026, director Aaron Royston received an equity compensation package from Achieve Life Sciences, Inc. consisting of a stock option grant for 25,000 shares of common stock at an exercise price of $6.18 per share and a separate grant of 16,700 restricted stock units, each RSU representing a right to receive one share of common stock upon settlement. Both the option and RSU awards vest 100% on the earlier of July 27, 2027 or immediately prior to the company’s 2027 annual meeting of stockholders, contingent on his continued service. These awards are held by Dr. Royston for the benefit of venBio Global Strategic Fund V, L.P., and he disclaims beneficial ownership beyond any pecuniary interest, with any proceeds from future exercises, vesting, and sales to be remitted to venBio V.

Filing Facts

CIK

949858

Ticker

ACHV

Form

4

Source Type

fda

Accession

0001193125-26-324253

Alert Tier

5